

## Q-linea AB appoints ABG Sundal Collier as liquidity provider

Q-linea AB (publ) (OMX: QLINEA) – Q-linea AB (the “Company”) has appointed ABG Sundal Collier (“ABGSC”) as liquidity provider for the Company’s shares listed on Nasdaq Stockholm.

The commitment takes place within the framework of Nasdaq Stockholm’s rules on liquidity providers. ABGSC undertakes to continuously during the opening hours quote prices for Q-linea’s share in accordance with the at all time prevailing minimum requirements for liquidity providers set out by Nasdaq Stockholm aiming at improving the liquidity of the share and reducing the spread. ABGSC’s assignment commences on April 3, 2023.

### For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB

[Jonas.Jarvius@qlinea.com](mailto:Jonas.Jarvius@qlinea.com)

+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB

[Anders.Lundin@qlinea.com](mailto:Anders.Lundin@qlinea.com)

+46 (0) 70-600 15 20

### About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit [www.qlinea.com](http://www.qlinea.com).

### Attachments

[Q-linea AB appoints ABG Sundal Collier as liquidity provider](#)